Skip to main content
SpringerLink
Log in

Suicide and Inflammation

  • Chapter
  • First Online:
Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1411))

Abstract

Suicide is a leading cause of death worldwide. Although the neurobiological dysfunction underlying suicidal behavior remains unclear, recent work suggests that the immune system may play a role in the pathophysiology of suicide. In this chapter, we discuss a nascent body of literature suggesting that peripheral and central nervous systems (CNS) inflammation are associated with suicidal behavior. Because early-life stress is a major risk factor for suicidal behavior and is also associated with immune dysregulation, we hypothesize that such immune dysregulation may be the mechanism by which childhood maltreatment leads to an increased risk of suicidal behavior and suicide. Targeting inflammatory processes may be a novel treatment strategy, especially in populations that have experienced childhood trauma and exhibit elevated inflammation. Future work should directly test the hypothesis that reducing inflammation would result in a reduction in suicidal behavior.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Suicide worldwide in 2019: global health estimates. Geneva: World Health Organization; 2019.

    Google Scholar 

  2. Hedegaard H, Curtin SC, Warner M. Suicide mortality in the United States, 1999-2019; 2021.

    Google Scholar 

  3. Shepard DS, Gurewich D, Lwin AK, Reed GA Jr, Silverman MM. Suicide and suicidal attempts in the United States: costs and policy implications. Suicide Life Threat Behav. 2016;46(3):352–62.

    Article  PubMed  Google Scholar 

  4. National strategy for suicide prevention: goals and objectives for action: a report of the U.S. Surgeon General and of the National Action Alliance for Suicide Prevention, 2012. Center for Disease Control; 2012.

    Google Scholar 

  5. World Health Organization. Preventing suicide: a global imperative. Geneva: World Health Organization; 2014.

    Google Scholar 

  6. Nock MK, Deming CA, Fullerton CS, Gilman SE, Goldenberg M, Kessler RC, et al. Suicide among soldiers: a review of psychosocial risk and protective factors. Psychiatry. 2013;76(2):97–125.

    Article  PubMed  Google Scholar 

  7. Carroll R, Metcalfe C, Gunnell D. Hospital presenting self-harm and risk of fatal and non-fatal repetition: systematic review and meta-analysis. PLoS One. 2014;9(2):e89944.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry. 2004;4:37.

    Article  PubMed  PubMed Central  Google Scholar 

  9. McGirr A, Renaud J, Seguin M, Alda M, Turecki G. Course of major depressive disorder and suicide outcome: a psychological autopsy study. J Clin Psychiatry. 2008;69(6):966–70.

    Article  PubMed  Google Scholar 

  10. Holma KM, Melartin TK, Haukka J, Holma IA, Sokero TP, Isometsa ET. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am J Psychiatry. 2010;167(7):801–8.

    Article  PubMed  Google Scholar 

  11. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(4 Suppl):81–90.

    Article  PubMed  PubMed Central  Google Scholar 

  12. McGirr A, Alda M, Seguin M, Cabot S, Lesage A, Turecki G. Familial aggregation of suicide explained by cluster B traits: a three-group family study of suicide controlling for major depressive disorder. Am J Psychiatry. 2009;166(10):1124–34.

    Article  PubMed  Google Scholar 

  13. Murphy K, Weaver C. Janeway’s immunobiology. New York: Garland Science; 2012.

    Google Scholar 

  14. MacGillivray DM, Kollmann TR. The role of environmental factors in modulating immune responses in early life. Front Immunol. 2014;5:434.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol. 2007;28(1):12–8.

    Article  CAS  PubMed  Google Scholar 

  17. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314–8.

    Article  CAS  PubMed  Google Scholar 

  18. Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018–27.

    Article  CAS  PubMed  Google Scholar 

  19. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol. 2011;11(11):775–87.

    Article  CAS  PubMed  Google Scholar 

  20. Tan CX, Eroglu C. Cell adhesion molecules regulating astrocyte-neuron interactions. Curr Opin Neurobiol. 2021;69:170–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  23. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ganong WF. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin Exp Pharmacol Physiol. 2000;27(5–6):422–7.

    Article  CAS  PubMed  Google Scholar 

  25. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C. Cytokine signals propagate through the brain. Mol Psychiatry. 2000;5(6):604–15.

    Article  CAS  PubMed  Google Scholar 

  26. Konsman JP, Vigues S, Mackerlova L, Bristow A, Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol. 2004;472(1):113–29.

    Article  PubMed  Google Scholar 

  27. Schiltz JC, Sawchenko PE. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci. 2002;22(13):5606–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Perez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15.

    Article  CAS  PubMed  Google Scholar 

  29. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

    Article  CAS  PubMed  Google Scholar 

  30. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16.

    Article  CAS  PubMed  Google Scholar 

  31. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–6.

    Article  CAS  PubMed  Google Scholar 

  32. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147(9):1577–80.

    Article  CAS  PubMed  Google Scholar 

  33. Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC, Gomes S, et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol. 2010;33(6):312–6.

    Article  CAS  PubMed  Google Scholar 

  34. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21(2):241–3.

    Article  CAS  PubMed  Google Scholar 

  35. Baron DA, Hardie T, Baron SH. Possible association of interleukin-2 treatment with depression and suicide. J Am Osteopath Assoc. 1993;93(7):799–800.

    CAS  PubMed  Google Scholar 

  36. Rifflet H, Vuillemin E, Oberti F, Duverger P, Lainé P, Garré JB, et al. [Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha]. Gastroenterol Clin Biol. 1998;22(3):353–7.

    Google Scholar 

  37. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun. 2004;18(3):205–13.

    Article  CAS  PubMed  Google Scholar 

  38. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry. 2004;26(3):237–40.

    Article  PubMed  Google Scholar 

  39. Stenager EN, Stenager E, Koch-Henriksen N, Brønnum-Hansen H, Hyllested K, Jensen K, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry. 1992;55(7):542–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41(8):1193–6.

    Article  CAS  PubMed  Google Scholar 

  41. Pompili M, Innamorati M, Trovarelli S, Narcisi A, Bellini S, Orsini D, et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J Int Med Res. 2016;44(1 Suppl):61–6.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32(3):188–90.

    Article  CAS  PubMed  Google Scholar 

  43. Picardi A, Lega I, Tarolla E. Suicide risk in skin disorders. Clin Dermatol. 2013;31(1):47–56.

    Article  PubMed  Google Scholar 

  44. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–5.

    PubMed  PubMed Central  Google Scholar 

  45. Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–9.e5.

    Article  CAS  PubMed  Google Scholar 

  46. Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260–7.

    Article  PubMed  Google Scholar 

  47. Lund-Sørensen H, Benros ME, Madsen T, Sørensen HJ, Eaton WW, Postolache TT, et al. A nationwide cohort study of the association between hospitalization with infection and risk of death by suicide. JAMA Psychiatry. 2016;73(9):912–9.

    Article  PubMed  Google Scholar 

  48. Dickerson F, Wilcox HC, Adamos M, Katsafanas E, Khushalani S, Origoni A, et al. Suicide attempts and markers of immune response in individuals with serious mental illness. J Psychiatr Res. 2017;87:37–43.

    Article  PubMed  Google Scholar 

  49. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Additive effects of elevated C-reactive protein and exposure to herpes simplex virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res. 2012;134(1):83–8.

    Article  PubMed  Google Scholar 

  50. Schretlen DJ, Vannorsdall TD, Winicki JM, Mushtaq Y, Hikida T, Sawa A, et al. Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. Schizophr Res. 2010;118(1–3):224–31.

    Article  PubMed  Google Scholar 

  51. Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB. Serological evidence of exposure to herpes simplex virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res. 2011;128(1-3):61–5.

    Article  PubMed  Google Scholar 

  52. Nissen J, Trabjerg B, Pedersen MG, Banasik K, Pedersen OB, Sørensen E, et al. Herpes simplex virus type 1 infection is associated with suicidal behavior and first registered psychiatric diagnosis in a healthy population. Psychoneuroendocrinology. 2019;108:150–4.

    Article  PubMed  Google Scholar 

  53. Carellos EV, de Andrade GM, Vasconcelos-Santos DV, Januário JN, Romanelli RM, Abreu MN, et al. Adverse socioeconomic conditions and oocyst-related factors are associated with congenital toxoplasmosis in a population-based study in Minas Gerais, Brazil. PLoS One. 2014;9(2):e88588.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ayi I, Sowah AO, Blay EA, Suzuki T, Ohta N, Ayeh-Kumi PF. Toxoplasma gondii infections among pregnant women, children and HIV-seropositive persons in Accra, Ghana. Trop Med Health. 2016;44:17.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Tong WH, Pavey C, O’Handley R, Vyas A. Behavioral biology of Toxoplasma gondii infection. Parasit Vectors. 2021;14(1):77.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Chaudhury A, Ramana BV. Schizophrenia and bipolar disorders: the toxoplasma connection. Trop Parasitol. 2019;9(2):71–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Postolache TT, Wadhawan A, Rujescu D, Hoisington AJ, Dagdag A, Baca-Garcia E, et al. Toxoplasma gondii, suicidal behavior, and intermediate phenotypes for suicidal behavior. Front Psychiatry. 2021;12:665682.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Zhang Y, Träskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N, et al. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. J Clin Psychiatry. 2012;73(8):1069–76.

    Article  CAS  PubMed  Google Scholar 

  59. Bak J, Shim SH, Kwon YJ, Lee HY, Kim JS, Yoon H, et al. The association between suicide attempts and Toxoplasma gondii infection. Clin Psychopharmacol Neurosci. 2018;16(1):95–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Yagmur F, Yazar S, Temel HO, Cavusoglu M. May Toxoplasma gondii increase suicide attempt-preliminary results in Turkish subjects? Forensic Sci Int. 2010;199(1–3):15–7.

    Article  PubMed  Google Scholar 

  61. Ling VJ, Lester D, Mortensen PB, Langenberg PW, Postolache TT. Toxoplasma gondii seropositivity and suicide rates in women. J Nerv Ment Dis. 2011;199(7):440–4.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Soleymani E, Faizi F, Heidarimoghadam R, Davoodi L, Mohammadi Y. Association of T. gondii infection with suicide: a systematic review and meta-analysis. BMC Public Health. 2020;20(1):766.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Amouei A, Moosazadeh M, Nayeri Chegeni T, Sarvi S, Mizani A, Pourasghar M, et al. Evolutionary puzzle of Toxoplasma gondii with suicidal ideation and suicide attempts: an updated systematic review and meta-analysis. Transbound Emerg Dis. 2020.

    Google Scholar 

  64. Meier TB, Savitz J. The Kynurenine pathway in traumatic brain injury: implications for psychiatric outcomes. Biol Psychiatry. 2022;91(5):449–58.

    Article  PubMed  Google Scholar 

  65. Holzer KJ, Carbone JT, DeLisi M, Vaughn MG. Traumatic brain injury and coextensive psychopathology: new evidence from the 2016 Nationwide Emergency Department Sample (NEDS). J Psychiatr Res. 2019;114:149–52.

    Article  PubMed  Google Scholar 

  66. Russell WR. Disability caused by brain wounds; a review of 1,166 cases. J Neurol Neurosurg Psychiatry. 1951;14(1):35–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Anstey KJ, Butterworth P, Jorm AF, Christensen H, Rodgers B, Windsor TD. A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms. J Clin Epidemiol. 2004;57(11):1202–9.

    Article  PubMed  Google Scholar 

  68. Silver JM, Kramer R, Greenwald S, Weissman M. The association between head injuries and psychiatric disorders: findings from the New Haven NIMH Epidemiologic Catchment Area Study. Brain Inj. 2001;15(11):935–45.

    Article  CAS  PubMed  Google Scholar 

  69. Teasdale TW, Engberg AW. Suicide after traumatic brain injury: a population study. J Neurol Neurosurg Psychiatry. 2001;71(4):436–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Fralick M, Sy E, Hassan A, Burke MJ, Mostofsky E, Karsies T. Association of concussion with the risk of suicide: a systematic review and meta-analysis. JAMA Neurol. 2019;76(2):144–51.

    Article  PubMed  Google Scholar 

  71. Black C, Miller BJ. Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol Psychiatry. 2015;78(1):28–37.

    Article  CAS  PubMed  Google Scholar 

  72. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.

    Article  PubMed  PubMed Central  Google Scholar 

  73. O’Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013;30(4):307–14.

    Article  PubMed  Google Scholar 

  74. Dolsen MR, Prather AA, Lamers F, Penninx B. Suicidal ideation and suicide attempts: associations with sleep duration, insomnia, and inflammation. Psychol Med. 2020:1–10.

    Google Scholar 

  75. Janelidze S, Mattei D, Westrin Å, Träskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25(2):335–9.

    Article  CAS  PubMed  Google Scholar 

  76. Rengasamy M, Zhong Y, Marsland A, Chen K, Douaihy A, Brent D, et al. Signaling networks in inflammatory pathways and risk for suicidal behavior. Brain Behav Immun Health. 2020;7:100122.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D. Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res. 2012;198(1):74–80.

    Article  PubMed  Google Scholar 

  78. Gabbay V, Klein RG, Guttman LE, Babb JS, Alonso CM, Nishawala M, et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol. 2009;19(4):423–30.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Isung J, Aeinehband S, Mobarrez F, Nordström P, Runeson B, Asberg M, et al. High interleukin-6 and impulsivity: determining the role of endophenotypes in attempted suicide. Transl Psychiatry. 2014;4(10):e470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135(5):373–87.

    Article  PubMed  Google Scholar 

  81. Monfrim X, Gazal M, De Leon PB, Quevedo L, Souza LD, Jansen K, et al. Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β? Bipolar Disord. 2014;16(7):741–7.

    Article  CAS  PubMed  Google Scholar 

  82. Ganança L, Galfalvy HC, Cisneros-Trujillo S, Basseda Z, Cooper TB, Ren X, et al. Relationships between inflammatory markers and suicide risk status in major depression. J Psychiatr Res. 2021;134:192–9.

    Article  PubMed  Google Scholar 

  83. Lu J, Li S, Li H, Mou T, Zhou L, Huang B, et al. Changes in plasma NPY, IL-1β and hypocretin in people who died by suicide. Neuropsychiatr Dis Treat. 2019;15:2893–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Coryell W, Wilcox H, Evans SJ, Pandey GN, Jones-Brando L, Dickerson F, et al. Aggression, impulsivity and inflammatory markers as risk factors for suicidal behavior. J Psychiatr Res. 2018;106:38–42.

    Article  PubMed  Google Scholar 

  85. Isung J, Mobarrez F, Nordström P, Asberg M, Jokinen J. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry. 2012;13(6):468–73.

    Article  PubMed  Google Scholar 

  86. Melhem NM, Munroe S, Marsland A, Gray K, Brent D, Porta G, et al. Blunted HPA axis activity prior to suicide attempt and increased inflammation in attempters. Psychoneuroendocrinology. 2017;77:284–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Nässberger L, Träskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr Scand. 1993;88(1):48–52.

    Article  PubMed  Google Scholar 

  88. Yang Y, Chen J, Liu C, Fang L, Liu Z, Guo J, et al. The extrinsic coagulation pathway: a biomarker for suicidal behavior in major depressive disorder. Sci Rep. 2016;6:32882.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Dupuy AM, Terrier N, Sénécal L, Morena M, Leray H, Canaud B, et al. [Is C-reactive protein a marker of inflammation?]. Nephrologie. 2003;24(7):337–41.

    Google Scholar 

  90. Ventorp F, Gustafsson A, Träskman-Bendz L, Westrin Å, Ljunggren L. Increased soluble urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters. PLoS One. 2015;10(10):e0140052.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Gibbs HM, Davis L, Han X, Clothier J, Eads LA, Cáceda R. Association between C-reactive protein and suicidal behavior in an adult inpatient population. J Psychiatr Res. 2016;79:28–33.

    Article  PubMed  Google Scholar 

  92. Park RJ, Kim YH. Association between high sensitivity CRP and suicidal ideation in the Korean general population. Eur Neuropsychopharmacol. 2017;27(9):885–91.

    Article  CAS  PubMed  Google Scholar 

  93. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun. 2011;25(6):1272–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Messaoud A, Mensi R, Douki W, Neffati F, Najjar MF, Gobbi G, et al. Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide. World J Biol Psychiatry. 2019;20(9):703–11.

    Article  PubMed  Google Scholar 

  95. Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landén M, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl Psychiatry. 2016;6(8):e865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Bradley KA, Case JA, Khan O, Ricart T, Hanna A, Alonso CM, et al. The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Res. 2015;227(2–3):206–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träskman-Bendz L, Guillemin GJ, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110–7.

    Article  CAS  PubMed  Google Scholar 

  98. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287–92.

    Article  CAS  PubMed  Google Scholar 

  99. Janelidze S, Suchankova P, Ekman A, Erhardt S, Sellgren C, Samuelsson M, et al. Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. Acta Psychiatr Scand. 2015;131(4):269–78.

    Article  CAS  PubMed  Google Scholar 

  100. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9(12):971–88.

    Article  CAS  PubMed  Google Scholar 

  102. Owen DR, Narayan N, Wells L, Healy L, Smyth E, Rabiner EA, et al. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. J Cereb Blood Flow Metab. 2017;37(8):2679–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72(3):268–75.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, et al. Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: a positron emission tomography study. Biol Psychiatry. 2018;83(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  105. Schubert JJ, Veronese M, Fryer TD, Manavaki R, Kitzbichler MG, Nettis MA, et al. A modest increase in (11)C-PK11195-positron emission tomography TSPO binding in depression is not associated with serum C-reactive protein or body mass index. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(7):716–24.

    PubMed  PubMed Central  Google Scholar 

  106. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res. 2012;46(1):57–63.

    Article  PubMed  Google Scholar 

  107. Pandey GN, Rizavi HS, Zhang H, Bhaumik R, Ren X. Abnormal protein and mRNA expression of inflammatory cytokines in the prefrontal cortex of depressed individuals who died by suicide. J Psychiatry Neurosci. 2018;43(6):376–85.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Hoyo-Becerra C, Huebener A, Trippler M, Lutterbeck M, Liu ZJ, Truebner K, et al. Concomitant interferon alpha stimulation and TLR3 activation induces neuronal expression of depression-related genes that are elevated in the brain of suicidal persons. PLoS One. 2013;8(12):e83149.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Clark SM, Pocivavsek A, Nicholson JD, Notarangelo FM, Langenberg P, McMahon RP, et al. Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J Psychiatry Neurosci. 2016;41(6):386–94.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand. 2008;117(3):198–206.

    Article  CAS  PubMed  Google Scholar 

  111. Pandey GN, Rizavi HS, Bhaumik R, Ren X. Innate immunity in the postmortem brain of depressed and suicide subjects: role of Toll-like receptors. Brain Behav Immun. 2019;75:101–11.

    Article  CAS  PubMed  Google Scholar 

  112. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151–7.

    Article  PubMed  Google Scholar 

  113. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun. 2014;42:50–9.

    Article  CAS  PubMed  Google Scholar 

  114. Brisch R, Steiner J, Mawrin C, Krzyżanowska M, Jankowski Z, Gos T. Microglia in the dorsal raphe nucleus plays a potential role in both suicide facilitation and prevention in affective disorders. Eur Arch Psychiatry Clin Neurosci. 2017;267(5):403–15.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Busse M, Busse S, Myint AM, Gos T, Dobrowolny H, Müller UJ, et al. Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? Eur Arch Psychiatry Clin Neurosci. 2015;265(4):321–9.

    Article  PubMed  Google Scholar 

  116. Torres-Platas SG, Hercher C, Davoli MA, Maussion G, Labonté B, Turecki G, et al. Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. Neuropsychopharmacology. 2011;36(13):2650–8.

    Article  PubMed  PubMed Central  Google Scholar 

  117. O’Leary LA, Belliveau C, Davoli MA, Ma JC, Tanti A, Turecki G, et al. Widespread decrease of cerebral vimentin-immunoreactive astrocytes in depressed suicides. Front Psychiatry. 2021;12:640963.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Cobb JA, O’Neill K, Milner J, Mahajan GJ, Lawrence TJ, May WL, et al. Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. Neuroscience. 2016;316:209–20.

    Article  CAS  PubMed  Google Scholar 

  119. Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018;55(5):4195–206.

    PubMed  Google Scholar 

  120. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Hiles SA, Baker AL, de Malmanche T, Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med. 2012;42(10):2015–26.

    Article  CAS  PubMed  Google Scholar 

  122. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532–43.

    Article  CAS  PubMed  Google Scholar 

  123. Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain Behav Immun. 2019;79:24–38.

    Article  CAS  PubMed  Google Scholar 

  124. Więdłocha M, Marcinowicz P, Krupa R, Janoska-Jaździk M, Janus M, Dębowska W, et al. Effect of antidepressant treatment on peripheral inflammation markers - a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt C):217–26.

    Article  PubMed  Google Scholar 

  125. Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107(2):234–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Syed SA, Beurel E, Loewenstein DA, Lowell JA, Craighead WE, Dunlop BW, et al. Defective inflammatory pathways in never-treated depressed patients are associated with poor treatment response. Neuron. 2018;99(5):914–24.e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, et al. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2009;10(4):313–23.

    Article  PubMed  Google Scholar 

  128. Lehtimäki K, Keränen T, Huuhka M, Palmio J, Hurme M, Leinonen E, et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT. 2008;24(1):88–91.

    Article  PubMed  Google Scholar 

  129. Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, et al. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021;49:122–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Wang SM, Kim NY, Na HR, Lim HK, Woo YS, Pae CU, et al. Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis. Clin Psychopharmacol Neurosci. 2021;19(2):341–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Nowak W, Grendas LN, Sanmarco LM, Estecho IG, Arena ÁR, Eberhardt N, et al. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR. EBioMedicine. 2019;50:290–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Köhler-Forsberg O, Lydholm CN, Hjorthøj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139(5):404–19.

    Article  PubMed  Google Scholar 

  133. Lehrer S, Rheinstein PH. Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce suicidal ideation and depression. Discov Med. 2019;28(154):205–12.

    PubMed  Google Scholar 

  134. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23(2):335–43.

    Article  CAS  PubMed  Google Scholar 

  135. Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, et al. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept. J Eur Acad Dermatol Venereol. 2013;27(1):125–8.

    Article  CAS  PubMed  Google Scholar 

  136. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35.

    Article  CAS  PubMed  Google Scholar 

  137. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103(12):3132–41.

    Article  PubMed  Google Scholar 

  138. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62(5):812–8.

    Article  CAS  PubMed  Google Scholar 

  139. Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75(3):506–15.

    Article  CAS  PubMed  Google Scholar 

  140. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–65.

    Article  CAS  PubMed  Google Scholar 

  141. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, et al. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease. Brain Behav Immun. 2017;66:156–64.

    Article  CAS  PubMed  Google Scholar 

  142. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(8):783–90.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Mansur RB, Delgado-Peraza F, Subramaniapillai M, Lee Y, Iacobucci M, Rodrigues N, et al. Extracellular vesicle biomarkers reveal inhibition of neuroinflammation by infliximab in association with antidepressant response in adults with bipolar depression. Cells. 2020;9(4):895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Services UDoHH. Child maltreatment; 2012.

    Google Scholar 

  146. McCloskey LA, Walker M. Posttraumatic stress in children exposed to family violence and single-event trauma. J Am Acad Child Adolesc Psychiatry. 2000;39(1):108–15.

    Article  CAS  PubMed  Google Scholar 

  147. Costello EJ, Angold A. Developmental psychopathology and public health: past, present, and future. Dev Psychopathol. 2000;12(4):599–618.

    Article  CAS  PubMed  Google Scholar 

  148. Nemeroff CB. Paradise lost: the neurobiological and clinical consequences of child abuse and neglect. Neuron. 2016;89(5):892–909.

    Article  CAS  PubMed  Google Scholar 

  149. Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med. 1998;14(4):245–58.

    Article  CAS  PubMed  Google Scholar 

  150. Dube SR, Anda RF, Felitti VJ, Chapman DP, Williamson DF, Giles WH. Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: findings from the Adverse Childhood Experiences Study. JAMA. 2001;286(24):3089–96.

    Article  CAS  PubMed  Google Scholar 

  151. Fergusson DM, Woodward LJ, Horwood LJ. Risk factors and life processes associated with the onset of suicidal behaviour during adolescence and early adulthood. Psychol Med. 2000;30(1):23–39.

    Article  CAS  PubMed  Google Scholar 

  152. Afifi TO, Enns MW, Cox BJ, Asmundson GJ, Stein MB, Sareen J. Population attributable fractions of psychiatric disorders and suicide ideation and attempts associated with adverse childhood experiences. Am J Public Health. 2008;98(5):946–52.

    Article  PubMed  PubMed Central  Google Scholar 

  153. McCauley J, Kern DE, Kolodner K, Dill L, Schroeder AF, DeChant HK, et al. Clinical characteristics of women with a history of childhood abuse: unhealed wounds. JAMA. 1997;277(17):1362–8.

    Article  CAS  PubMed  Google Scholar 

  154. Brezo J, Paris J, Tremblay R, Vitaro F, Hébert M, Turecki G. Identifying correlates of suicide attempts in suicidal ideators: a population-based study. Psychol Med. 2007;37(11):1551–62.

    Article  PubMed  Google Scholar 

  155. Isohookana R, Riala K, Hakko H, Räsänen P. Adverse childhood experiences and suicidal behavior of adolescent psychiatric inpatients. Eur Child Adolesc Psychiatry. 2013;22(1):13–22.

    Article  PubMed  Google Scholar 

  156. Lin D, Li X, Fan X, Fang X. Child sexual abuse and its relationship with health risk behaviors among rural children and adolescents in Hunan, China. Child Abuse Negl. 2011;35(9):680–7.

    Article  PubMed  Google Scholar 

  157. Chen LP, Murad MH, Paras ML, Colbenson KM, Sattler AL, Goranson EN, et al. Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc. 2010;85(7):618–29.

    Article  PubMed  PubMed Central  Google Scholar 

  158. Copeland WE, Wolke D, Angold A, Costello EJ. Adult psychiatric outcomes of bullying and being bullied by peers in childhood and adolescence. JAMA Psychiatry. 2013;70(4):419–26.

    Article  PubMed  PubMed Central  Google Scholar 

  159. Brezo J, Paris J, Vitaro F, Hébert M, Tremblay RE, Turecki G. Predicting suicide attempts in young adults with histories of childhood abuse. Br J Psychiatry. 2008;193(2):134–9.

    Article  PubMed  Google Scholar 

  160. Turecki G. The molecular bases of the suicidal brain. Nat Rev Neurosci. 2014;15(12):802–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom Med. 2009;71(2):243–50.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Paras ML, Murad MH, Chen LP, Goranson EN, Sattler AL, Colbenson KM, et al. Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. JAMA. 2009;302(5):550–61.

    Article  CAS  PubMed  Google Scholar 

  163. Leserman J, Drossman DA, Li Z, Toomey TC, Nachman G, Glogau L. Sexual and physical abuse history in gastroenterology practice: how types of abuse impact health status. Psychosom Med. 1996;58(1):4–15.

    Article  CAS  PubMed  Google Scholar 

  164. Dong M, Giles WH, Felitti VJ, Dube SR, Williams JE, Chapman DP, et al. Insights into causal pathways for ischemic heart disease: adverse childhood experiences study. Circulation. 2004;110(13):1761–6.

    Article  PubMed  Google Scholar 

  165. Padgett DA, Glaser R. How stress influences the immune response. Trends Immunol. 2003;24(8):444–8.

    Article  CAS  PubMed  Google Scholar 

  166. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol. 2002;20:125–63.

    Article  CAS  PubMed  Google Scholar 

  167. Shanks N, Lightman SL. The maternal-neonatal neuro-immune interface: are there long-term implications for inflammatory or stress-related disease? J Clin Invest. 2001;108(11):1567–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630–3.

    Article  PubMed  Google Scholar 

  169. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A. 2007;104(4):1319–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008;65(4):409–15.

    Article  PubMed  PubMed Central  Google Scholar 

  171. Crosswell AD, Bower JE, Ganz PA. Childhood adversity and inflammation in breast cancer survivors. Psychosom Med. 2014;76(3):208–14.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Slopen N, Kubzansky LD, McLaughlin KA, Koenen KC. Childhood adversity and inflammatory processes in youth: a prospective study. Psychoneuroendocrinology. 2013;38(2):188–200.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Dell Medical School, Austin, TX, USA

    Jennifer J. Donegan & Charles B. Nemeroff

  2. Department of Neuroscience, University of Texas at Austin, Dell Medical School, Austin, TX, USA

    Jennifer J. Donegan

Authors
  1. Jennifer J. Donegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles B. Nemeroff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles B. Nemeroff .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Korea University Ansan Hospital, Ansan, Korea (Republic of)

    Yong-Ku Kim

Ethics declarations

This work was supported by grants R00MH121355 (J.J.D.) and R01MH117293 (C.B.N) from the National Institute of Mental Health.

Dr. Nemeroff’s financial disclosures are as follows: Dr. Nemeroff has provided consulting to ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Sage, BioXcel Therapeutics, SILO Pharma, XW Pharma, Neuritek, Engrail Therapeutics, Inc., Corcept Therapeutics Pharmaceuticals Company, SK Life Science Inc, Alfasigma, and Pasithea Therapeutics Corp. Dr. Nemeroff holds stock in the following companies: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, and TRUUST Neuroimaging. Dr. Nemeroff serves on the scientific advisory board of ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, Heading Health, TRUUST Neuroimaging, and Pasithea Therapeutics Corp. He is on the Board of Directors at Gratitude America, ADAA, and Xhale Smart, Inc. Dr. Nemeroff holds the following patents: method and devices for transdermal delivery of lithium (US 6,375,990B1) and method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Donegan, J.J., Nemeroff, C.B. (2023). Suicide and Inflammation. In: Kim, YK. (eds) Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders. Advances in Experimental Medicine and Biology, vol 1411. Springer, Singapore. https://doi.org/10.1007/978-981-19-7376-5_17

Download citation

Publish with us

Policies and ethics

Search

Navigation